Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Biomarkers are needed to assist in the diagnosis and medical management of various neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and dementia with Lewy body (DLB). We have employed a multiplex quantitative proteomics method, iTRAQ (isobaric Tagging for Relative and Absolute protein Quantification), in conjunction with multidimensional chromatography, followed by tandem mass spectrometry (MS/MS), to simultaneously measure relative changes in the proteome of cerebrospinal fluid (CSF) obtained from patients with AD, PD, and DLB compared to healthy controls. The diagnosis of AD and DLB was confirmed by autopsy, whereas the diagnosis of PD was based on clinical criteria. The proteomic findings showed quantitative changes in AD, PD, and DLB as compared to controls; among more than 1,500 identified CSF proteins, 136, 72, and 101 of the proteins displayed quantitative changes unique to AD, PD, and DLB, respectively. Eight unique proteins were confirmed by Western blot analysis, and the sensitivity at 95% specificity was calculated for each marker alone and in combination. Several panels of unique makers were capable of distinguishing AD, PD and DLB patients from each other as well as from controls with high sensitivity at 95% specificity. Although these preliminary findings must be validated in a larger and different population of patients, they suggest that a roster of proteins may be generated and developed into specific biomarkers that could eventually assist in clinical diagnosis and monitoring disease progression of AD, PD and DLB.

[1]  G. Small,et al.  In vivo brain imaging of tangle burden in humans , 2002, Journal of Molecular Neuroscience.

[2]  T. Montine,et al.  Characterization of proteome of human cerebrospinal fluid. , 2006, International review of neurobiology.

[3]  James P. Malone,et al.  Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S , 2005, Molecular & Cellular Proteomics.

[4]  K. Blennow.  CSF biomarkers for Alzheimer’s disease: use in early diagnosis and evaluation of drug treatment , 2005, Expert review of molecular diagnostics.

[5]  M. Sjögren,et al.  The Use of Proteomics in Biomarker Discovery in Neurodegenerative Diseases , 2005, Disease markers.

[6]  T. Montine,et al.  Microglia Lacking E Prostanoid Receptor Subtype 2 Have Enhanced Aβ Phagocytosis yet Lack Aβ-Activated Neurotoxicity , 2005 .

[7]  K. Blennow,et al.  CSF biomarkers for mild cognitive impairment and early Alzheimer's disease , 2005, Clinical Neurology and Neurosurgery.

[8]  Jing Zhang,et al.  Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid , 2005, Neurobiology of Aging.

[9]  P. Thomas,et al.  Coagulation and inflammatory markers in Alzheimer's and vascular dementia , 2005, International journal of clinical practice.

[10]  Jing Zhang,et al.  Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. , 2005, Journal of Alzheimer's disease : JAD.

[11]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[12]  P. Bauer,et al.  Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease , 2004, Neurology.

[13]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[14]  R. Neumar,et al.  Proteins released from degenerating neurons are surrogate markers for acute brain damage , 2004, Neurobiology of Disease.

[15]  S. Hunsucker,et al.  Proteomic analysis of multiple sclerosis cerebrospinal fluid , 2004, Multiple sclerosis.

[16]  S. Love.  Post mortem sampling of the brain and other tissues in neurodegenerative disease , 2004, Histopathology.

[17]  Kaj Blennow,et al.  Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. , 2003, Brain research. Molecular brain research.

[18]  J. Galvin.  Dementia with Lewy bodies. , 2003, Archives of neurology.

[19]  D. Hochstrasser,et al.  A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.

[20]  Margaret Sullivan Pepe,et al.  Combining Several Screening Tests: Optimality of the Risk Score , 2002, Biometrics.

[21]  B. Hyman,et al.  Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative , 2002, Journal of neuropathology and experimental neurology.

[22]  B. Hyman,et al.  Imaging Amyloid-β Deposits In Vivo , 2002 .

[23]  Kelvin H. Lee,et al.  Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease , 2002, Electrophoresis.

[24]  Kaj Blennow,et al.  Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients , 2002, Neuroreport.

[25]  D. Desiderio,et al.  Analysis of the human lumbar cerebrospinal fluid proteome , 2002, Electrophoresis.

[26]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[27]  C. Buhmann,et al.  Characterization of four lipoprotein classes in human cerebrospinal fluid. , 2001, Journal of lipid research.

[28]  J. Rogers,et al.  Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. , 2000, Brain research. Molecular brain research.

[29]  D. Hochstrasser,et al.  The dynamic range of protein expression: A challenge for proteomic research , 2000, Electrophoresis.

[30]  J. Jankovic,et al.  The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. , 2000, Archives of neurology.

[31]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[32]  K. Jellinger,et al.  Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. , 1998, Archives of neurology.

[33]  A. D. Smith,et al.  Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases , 1998, Journal of Neural Transmission.

[34]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.

[35]  T Suenaga,et al.  Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients. , 1996, Stroke.

[36]  D. Salmon,et al.  Clinical and Neuropathological Findings in Lewy Body Dementias , 1996, Brain and Cognition.

[37]  L. Pantoni,et al.  Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients. , 1995, Acta Neurologica Scandinavica.

[38]  G. Mashour,et al.  Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. , 1994, Alzheimer disease and associated disorders.

[39]  K. Blennow,et al.  Protein Analysis in Cerebrospinal Fluid , 1993 .

[40]  M. Somerville,et al.  Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. , 1992, Brain research. Molecular brain research.

[41]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[42]  A. Rajput,et al.  Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[43]  B. Reisberg,et al.  Mild cognitive impairment in the elderly , 1991, Neurology.

[44]  E. Thompson,et al.  A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. , 1990, Brain : a journal of neurology.

[45]  S. Matsuyama,et al.  Haptoglobin phenotypes in dementia of the Alzheimer type. , 1986, Human heredity.

[46]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[47]  R. Reitan.  Validity of the Trail Making Test as an Indicator of Organic Brain Damage , 1958 .